Peptide modified geniposidic acid targets bone and effectively promotes osteogenesis
Abstracts: Background: Geniposidic acid (GPA), one of the active components of Eucommia ulmoides, promote bone formation and treat osteoporosis by activating farnesoid X receptor (FXR). However, GPA has low oral availability and lack of bone targeting in the treatment of bone related diseases. With the development of modern technology, small molecules, amino acids, or aptamers are used for biological modification of drugs and target cells in bone tissue, which has become the trend of bone targeted research. Methods: In this study, SDSSD (an osteoblast-targeting peptide) were modified in GPA using Fmoc solid-phase synthesis technique to form a new SDSSD-GPA conjugate (SGPA). The bone targeting of SGPA was evaluated using in vivo imaging and cell co-culture. In vitro, the effect of SGPA on cytotoxicity, osteoblastic activity, and mineralization ability were studied in mouse primary osteoblasts (OBs). In vivo, the therapeutic effect of SGPA on osteoporosis using an ovariectomized (OVX) mouse model. The bone mass, histomorphometry, serum biochemical parameters, and the molecular mechanism were evaluated. Results: SGPA was enriched in OBs and tends to accumulate in bone tissue. In vitro, SGPA significantly enhanced the osteogenic activity and mineralization of OBs compared with GPA. In vivo, SGPA enhanced serum BALP and P1NP levels, increased the trabecular bone mass of the mice, and SGPA administration have a higher bone mineralization deposition rate than the GPA-treated mice. Moreover, SGPA significantly activated FXR and Runt-related transcription factor 2 (RUNX2). Conclusions: Collectively, SGPA is enriched into OBs, and promotes bone formation by activating FXR-RUNX2 signalling, effectively treating osteoporosis at relatively low doses. The translational potential of this article: This study demonstrates a more efficient and safe application of GPA in treating osteoporosis, provide a new concept for the bone targeted application of natural compounds..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Journal of Orthopaedic Translation - 38(2023), Seite 23-31 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Meijing Liu [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Bone targeting |
|---|
| doi: |
10.1016/j.jot.2022.07.007 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ080090273 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ080090273 | ||
| 003 | DE-627 | ||
| 005 | 20230310174829.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230310s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jot.2022.07.007 |2 doi | |
| 035 | |a (DE-627)DOAJ080090273 | ||
| 035 | |a (DE-599)DOAJe0f3610be60048a69e194aae25cc8b5b | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC925-935 | |
| 100 | 0 | |a Meijing Liu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Peptide modified geniposidic acid targets bone and effectively promotes osteogenesis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstracts: Background: Geniposidic acid (GPA), one of the active components of Eucommia ulmoides, promote bone formation and treat osteoporosis by activating farnesoid X receptor (FXR). However, GPA has low oral availability and lack of bone targeting in the treatment of bone related diseases. With the development of modern technology, small molecules, amino acids, or aptamers are used for biological modification of drugs and target cells in bone tissue, which has become the trend of bone targeted research. Methods: In this study, SDSSD (an osteoblast-targeting peptide) were modified in GPA using Fmoc solid-phase synthesis technique to form a new SDSSD-GPA conjugate (SGPA). The bone targeting of SGPA was evaluated using in vivo imaging and cell co-culture. In vitro, the effect of SGPA on cytotoxicity, osteoblastic activity, and mineralization ability were studied in mouse primary osteoblasts (OBs). In vivo, the therapeutic effect of SGPA on osteoporosis using an ovariectomized (OVX) mouse model. The bone mass, histomorphometry, serum biochemical parameters, and the molecular mechanism were evaluated. Results: SGPA was enriched in OBs and tends to accumulate in bone tissue. In vitro, SGPA significantly enhanced the osteogenic activity and mineralization of OBs compared with GPA. In vivo, SGPA enhanced serum BALP and P1NP levels, increased the trabecular bone mass of the mice, and SGPA administration have a higher bone mineralization deposition rate than the GPA-treated mice. Moreover, SGPA significantly activated FXR and Runt-related transcription factor 2 (RUNX2). Conclusions: Collectively, SGPA is enriched into OBs, and promotes bone formation by activating FXR-RUNX2 signalling, effectively treating osteoporosis at relatively low doses. The translational potential of this article: This study demonstrates a more efficient and safe application of GPA in treating osteoporosis, provide a new concept for the bone targeted application of natural compounds. | ||
| 650 | 4 | |a Geniposidic acid | |
| 650 | 4 | |a SDSSD | |
| 650 | 4 | |a Bone targeting | |
| 650 | 4 | |a Osteogenesis | |
| 653 | 0 | |a Diseases of the musculoskeletal system | |
| 700 | 0 | |a Danqi Zhu |e verfasserin |4 aut | |
| 700 | 0 | |a Fujun Jin |e verfasserin |4 aut | |
| 700 | 0 | |a Shuang Li |e verfasserin |4 aut | |
| 700 | 0 | |a Xiangning Liu |e verfasserin |4 aut | |
| 700 | 0 | |a Xiaogang Wang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Journal of Orthopaedic Translation |d Elsevier, 2016 |g 38(2023), Seite 23-31 |w (DE-627)DOAJ000146536 |x 22140328 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2023 |g pages:23-31 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jot.2022.07.007 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/e0f3610be60048a69e194aae25cc8b5b |z kostenfrei |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S2214031X22000705 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2214-031X |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2023 |h 23-31 | ||